TearSolutions, Inc.

TearSolutions’ proprietary protein is to Dry Eye Disease as insulin is to Type I Diabetes. Our lead product is well-poised to disrupt the $6B+ Dry Eye market.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Charlottesville, VA, USA
  • Currency USD
  • Founded July 2014
  • Employees 6
  • Incorporation Type C-corp
  • Website tearsolutions.com

Company Summary

Just as insulin was discovered to be the missing protein in Type I Diabetes, our founder discovered the missing protein in ALL forms of Dry Eye Disease (DED), which has been independently validated by leading experts in DED. TearSolutions' science has been supported by ~$13M of non-dilutive NIH funding and the company has raised ~$25M. With a promising first-in-human study completed, we are now raising $10M to run a phase II dose-ranging study.

Team

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free